Immuno-Genic Corporation, a Florida based Medical Device Research and Development Company currently holding one (1) U.S. and twenty-three (23) Foreign Patents on its Technology and the usage of its applied Therapeutic wavelength, is seeking investment(s) to facilitate finalization of the FDA Clearance to Market process, for completion of Phase IV product development and manufacturing, and to aggressively bring its Technology and its unique Therapeutic Medical Modality to market.
If you are an Investor, or know of an Investor desiring a unique and immediate investment opportunity geared toward the technological future of medicine, would you please take a few minutes and read over the following. I sincerely believe you may become quite interested in the potentially high ROI of this offering and of the potentials and possibilities presented by a ground floor investment in the future of medical science.
Raising $500K Bridge and $2.5M 2nd-3rd year - PPM - Terms Negotiable.
Minimum equity investment threshold $25,000.
A Substantial Equity Position is being offered for full-raise investment.
This is a Novel and Breakthrough Technology with world-wide market applications both in Human and Veterinary Medicine. The Modality/Device is Veterinarian proven with over 250,000 treatments having been successfully applied in Vet clinics over the past 10 years of research and limited sales. Treatments with the Device have shown consistent and positive resolutions to injuries, ailments and disease with an 80%+ success rate and with no negative side effects having been reported. Both Clinical and anecdotal treatments on human subjects have displayed the same remarkable results.
The Device is currently Phase III completed and FDA Compliant as a Veterinary Medical Modality, and less than 1 year away from FDA Clearance to Market in Human Medicine.
Company is Veterinary and Human Medicine device design, engineering and prototype ready/completed.
Upon adequate Funding the Veterinary Device will immediately be manufactured and aggressively marketed throughout the Veterinary Medical field, and, after receiving our FDA Clearance to Market for Human Medicine Usage, the Modality will be introduced into the Human Medical marketplace within a year. The Modality is currently being sold in the Veterinary Market in limited numbers where it has already proven its efficacy, marketability and profitability.
An existing agreement with a Major Medical Device Manufacturer is in place so that manufacturing of the newly designed and engineered Veterinary and Human Medical “Ig” Devices may begin as soon as the requested funding is achieved.
This Device is a “one of a kind” Medical Modality. It is a Disruptive Technology and a Technological Breakthrough in the field of Immune Modulation Therapy (IMT). Based on Quantum Physics, and Laser and Light Science the Technology has the unique ability to non-invasively stimulate and up-modulate the Immune System and the Immune Response (in animal or human subjects) through the photo-manipulation of molecules involved in the generation and production of the cellular communicator, nitric oxide.
This is not your father's Oldsmobile.
This is a serious Phase IV investment level opportunity. The company has already expended over $4M and 10+ years of hard work and sweat equity in bringing itself and the Technology to where it is today. The company is currently poised for increased manufacturing, sales growth, licensing, partnership and/or a buy out. We are seeking immediate Bridge Funding and mid-late stage developmental growth capital investiture, not "second" or "third round only" investment, please consider this before contacting.
The Company is poised and ready to move ahead... now.
Worldwide marketing of this Technology will have a multi-million-to-billion dollar profit potential. This profitability projection is based on a 58-62% profit margin computed against current unit costs of production and a 1<2% market penetration. Manufacturing costs should reduce significantly as market share and unit manufacturing increase, and as envisioned technological improvements, manufacturing techniques and component designs evolve.
Further, when the requested $3M funding is received, IGC will set up a non-profit Philanthropic humanitarian medical entity and five percent of all Human Market Ig Devices manufactured will be donated and freely placed with doctors in American and other medically deprived and disaster regions in need of immediate or long term medical aid so that even the poorest amongst us will be able to share in the benefits derived from the improved healthcare and quality of life offered by this Technology.
Time is money, so I will not spend any more of yours for now. I’ve given you the “gist” of it and it is now up to you.
Thanks in advance for any considerations you may give to joining this project.
For answers to your questions or for more complete Information: NDA, Executive Summary, Business Plan, Pro-Forma etc., please reply to:
Lee Brown, Corporate Secretary Managing Director R&D/Manufacturing
Immuno-Genic Corporation 921 South Ridgewood Avenue Daytona Beach, Florida 32114 USA LeeBrown at Immuno-Genic dot com Immuno-Genic dot com Tel 1-386-492-4836 FAX 1-386-492-4837 Cell 1-386-804-1709